Skip to Content

Felipe Samaniego, M. D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas M.D. Anderson Cancer Center
7455 Fannin St
Unit 903
Houston, TX 77054
Room Number: SCR2.2026
Phone: 713-792-3510
Fax: 713-563-7314

Education & Training

Degree-Granting Education

1983 Harvard Medical School, Boston, MA, MD, Medicine
1983 Harvard School of Public Health, Boston, MA, MPH, Health Services
1978 New Mexico State University, Las Cruces, NM, BS, Biology

Postgraduate Training

1990-1995 RESEARCH FELLOW, Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, NIH, Bethesda, MD
1986-1990 CLINICAL FELLOW, Hematology-Oncology, Hematology-Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
1984-1986 RESIDENT, University of Colorado Health Sciences Center, Denver, CO
1983-1984 INTERN, University of Colorado Health Sciences Center, Denver, CO

Board Certifications

1989 American Board of Medical Oncology
1986 American Board of Internal Medicine


Academic Appointments

Assistant Professor, Department of Immunology, University of Texas M.D. Anderson Cancer Center, Houston, TX, 2003-2006
Assistant Professor, Human Virology, Institute of Human Virology, University of Maryland Medical Center, Maryland, MD, 1996-1999

Honors and Awards

2011 US News and World Report Top Docs
2002 AACR-MICR Council Member, AACR-MICR
1989 Daland Fellowship, Alternate Fellow
1989 Robert Wood Johnson Foundation Fellow

Selected Publications

Peer-Reviewed Original Research Articles

1. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer. e-Pub 6/2016. PMID: 27351173.
2. Cheah CY, Chihara D, Ahmed M, Davis RE, Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol. e-Pub 1/2016. PMID: 26802151.
3. Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, Fayad L, Samaniego F, Turturro F, Oki Y, Chen W, Badillo M, Nomie K, DeLa Rosa M, Zhao D, Lam L, Addison A, Zhang H, Young KH, Li S, Santos D, Medeiros LJ, Champlin R, Romaguera J, Zhang L. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 17(1):48-56, 1/2016. e-Pub 11/28/2015. PMID: 26640039.
4. Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80-8, 1/2016. e-Pub 12/9/2015. PMID: 26648336.
5. Moore JA, Moore MB, Samaniego F, Pinnix CC, Moore DF. Small lymphocytic lymphoma presenting with hypopituitarism. Am J Med 129(1):e9-e10, 1/2016. e-Pub 9/5/2015. PMID: 26344628.
6. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE, Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 12/2015. e-Pub 9/2015. PMCID: PMC4715651.
7. Tanese K, Hashimoto Y, Berkova Z, Wang Y, Samaniego F, Lee JE, Ekmekcioglu S, Grimm EA. Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ. J Invest Dermatol 135(11):2775-84, 11/2015. e-Pub 6/2015. PMCID: PMC4640965.
8. Fowler NH, Nastoupil LJ, Hagemeister FB, Neelapu SS, Fayad LE, LeBlanc D, Samaniego F, Cheah CY. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma. Haematologica 100(11):e454-7, 11/2015. e-Pub 8/2015. PMCID: PMC4825296.
9. Oki Y, Fanale M, Romaguera J, Fayad L, Fowler N, Copeland A, Samaniego F, Kwak LW, Neelapu S, Wang M, Feng L, Younes A. Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. Br J Haematol 171(4):463-70, 11/2015. e-Pub 7/2015. PMID: 26213141.
10. Chihara D, Pro B, Loghavi S, Miranda RN, Medeiros LJ, Fanale MA, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Neelapu SS, Younes A, Fowler NH, Rodriguez MA, Wang M, Kwak LW, McLaughlin P, Dang NH, Oki Y. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol 171(4):509-16, 11/2015. e-Pub 8/2015. PMID: 26260306.
11. Oki Y, Younes A, Knickerbocker J, Samaniego F, Nastoupil L, Hagemeister F, Romaguera J, Fowler N, Kwak L, Westin J. Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma. Haematologica 100(7):e272-4, 7/2015. e-Pub 3/2015. PMCID: PMC4486240.
12. Samaniego F, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Berkova Z, Khashab T, Sehgal L, Vega-Vasquez F, Kwak LW. Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas. Br J Haematol 169(6):814-23, 6/2015. e-Pub 3/2015. PMID: 25828695.
13. Zhu H, Berkova Z, Mathur R, Sehgal L, Khashab T, Tao RH, Ao X, Feng L, Sabichi AL, Blechacz B, Rashid A, Samaniego F. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer. Mol Cancer Res 13(5):809-18, 5/2015. e-Pub 2/2015. PMID: 25678597.
14. Berkova Z, Wang S, Sehgal L, Patel KP, Prakash O, Samaniego F. Lymphoid hyperplasia and lymphoma in KSHV K1 transgenic mice. Histol Histopathol 30(5):559-68, 5/2015. e-Pub 10/2014. PMID: 25301266.
15. Westin JR, McLaughlin P, Romaguera J, Hagemeister FB, Pro B, Dang NH, Samaniego F, Rodriguez MA, Fayad L, Oki Y, Fanale M, Fowler N, Nastoupil L, Feng L, Loyer E, Younes A. Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 167(2):177-84, 5/2015. PMID: 25039868.
16. Oki Y, Ewer MS, Lenihan DJ, Fisch MJ, Hagemeister FB, Fanale M, Romaguera J, Pro B, Fowler N, Younes A, Astrow AB, Huang X, Kwak LW, Samaniego F, McLaughlin P, Neelapu SS, Wang M, Fayad LE, Durand JB, Rodriguez MA. Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Label, Single Arm, Phase II Trial. Clin Lymphoma Myeloma Leuk 15(3):152-8, 3/2015. e-Pub 9/28/2014. PMCID: PMC4344896.
17. Braun FK, Mathur R, Sehgal L, Wilkie-Grantham R, Chandra J, Berkova Z, Samaniego F. Inhibition of Methyltransferases Accelerates Degradation of cFLIP and Sensitizes B-Cell Lymphoma Cells to TRAIL-Induced Apoptosis. PLoS One 10(3):e0117994, 2015. e-Pub 3/2015. PMCID: PMC4349737.
18. Khashab T, Sehgal L, Medeiros LJ, Samaniego F. Spontaneous regression of interdigitating dendritic sarcoma in a patient with concurrent small lymphocytic lymphoma. BMJ Case Rep 2015, 2015. e-Pub 6/2015. PMID: 26071439.
19. Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, Rodriguez MA, Fayad L, Neelapu SS, Samaniego F. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol 8:63, 2015. e-Pub 6/2015. PMCID: PMC4460883.
20. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. e-Pub 6/18/2014. PMID: 24943107.
21. Sehgal L, Mukhopadhyay A, Rajan A, Khapare N, Sawant M, Vishal SS, Bhatt K, Ambatipudi S, Antao N, Alam H, Gurjar M, Basu S, Mathur R, Borde L, Hosing AS, Vaidya MM, Thorat R, Samaniego F, Kolthur-Seetharam U, Dalal SN. 14-3-3γ meditated transport of plakoglobin to the cell border is required for the initiation of desmosome assembly in vitro and in vivo. J Cell Sci 127(Pt 10):2174-88, 5/15/2014. e-Pub 3/7/2014. PMID: 24610948.
22. Nasser QJ, Pfeiffer ML, Romaguera J, Fowler N, Debnam JM, Samaniego F, El-Sawy T, McLaughlin P, Bakhoum MF, Esmaeli B. Clinical Value of Magnetic Resonance Imaging and Other Baseline Testing for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma. Leuk Lymphoma 55(5):1013-7, 5/2014. e-Pub 8/28/2013. PMID: 23879202.
23. Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, Neelapu S, Kwak LW, Samaniego F. FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia. e-Pub 4/2014. PMID: 24811343.
24. Oki Y, Chuang H, Chasen B, Jessop A, Pan T, Fanale M, Dabaja B, Fowler N, Romaguera J, Fayad L, Hagemeister F, Rodriguez MA, Neelapu S, Samaniego F, Kwak L, Younes A. The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. Br J Haematol 165(1):112-6, 4/2014. e-Pub 1/6/2014. PMID: 24386943.
25. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE, Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 1/2014. e-Pub 12/11/2013. PMCID: PMC3922714.
26. Hagemeister F, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Medeiros LJ, Pro B, Romaguera J, Samaniego F, Silverman JA, Sarris A, Cabanillas F. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol 162(5):631-8, 9/2013. e-Pub 6/27/2013. PMID: 23802738.
27. Wise JF, Berkova Z, Mathur R, Zhu H, Braun FK, Tao RH, Sabichi AL, Ao X, Maeng H, Samaniego F. Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex. Blood. e-Pub 4/18/2013. PMID: 23599269.
28. Westin JR, Thompson MA, Cataldo VD, Fayad LE, Fowler N, Fanale MA, Neelapu S, Samaniego F, Romaguera J, Shah J, McLaughlin P, Pro B, Kwak LW, Sanjorjo P, Murphy WA, Jimenez C, Toth B, Dong W, Hagemeister FB. Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial. Clin Lymphoma Myeloma Leuk, 4/2013. PMID: 23276888.
29. Batty N, Ghonimi E, Feng L, Fayad L, Younes A, Rodriguez MA, Romaguera JE, McLaughlin P, Samaniego F, Kwak LW, Hagemeister FB. The Absolute Monocyte and Lymphocyte Prognostic Index for Patients With Diffuse Large B-Cell Lymphoma Who Receive R-CHOP. Clin Lymphoma Myeloma Leuk, 2/2013. PMID: 23137719.
30. Oellers P, Savar A, Samaniego F, Pro B, Esmaeli B. Second-Line 90Yttrium-Ibritumomab Tiuxetan (Zevalin) in a Patient With Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma Refractory to Rituximab. Ophthal Plast Reconstr Surg 28(6):e145-6, 11/2012. PMID: 22820440.
31. Daniluk U, Kerros C, Tao RH, Wise JF, Ao X, Berkova Z, Samaniego F. The peptide derived from the Ig-like domain of human herpesvirus 8 K1 protein induces death in hematopoietic cancer cells. J Exp Clin Cancer Res 31(1):69, 8/2012. PMID: 22929310.
32. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS, Samaniego F, McLaughlin P, Fanale M, Younes A, Cabanillas F, Fowler N, Newberry KJ, Sun L, Young KH, Champlin R, Kwak L, Feng L, Badillo M, Bejarano M, Hartig K, Chen W, Chen Y, Byrne C, Bell N, Zeldis J, Romaguera J. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 13(7):716-23, 7/2012. PMID: 22677155.
33. Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol 23(6):1640-5, 6/2012. PMID: 22015451.
34. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood, 6/2012. PMID: 22586182.
35. Batty N, Hagemeister FB, Feng L, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study. Leuk Lymphoma 53(5):801-6, 5/2012. PMID: 22023528.
36. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Shabib Dabaja B, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood, 3/2012. PMID: 22371887.
37. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer 118(4):1023-31, 2/2012. PMID: 21761401.
38. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, Vega F. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 30(49):4874-86, 12/2011. PMCID: PMC3165099.
39. Wang J, Han F, Wu J, Lee SW, Chan CH, Wu CY, Yang WL, Gao Y, Zhang X, Jeong YS, Moten A, Samaniego F, Huang P, Liu Q, Zeng YX, Lin HK. The role of Skp2 in hematopoietic stem cell quiescence, pool size, and self-renewal. Blood 118(20):5429-38, 11/2011. PMCID: PMC3217347.
40. Tao RH, Berkova Z, Wise JF, Rezaeian AH, Daniluk U, Ao X, Hawke DH, Karp JE, Lin HK, Molldrem JJ, Samaniego F. PMLRARα binds to Fas and suppresses Fas-mediated apoptosis through recruiting c-FLIP in vivo. Blood 118(11):3107-18, 9/2011. PMID: 21803845.
41. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. Br J Haematol 154(2):284-6, 7/2011. PMID: 21517809.
42. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200-8, 7/2010. PMID: 20528872.
43. Ho HH, Savar A, Samaniego F, Manning J, Kasyan A, Pro B, Esmaeli B. Treatment of benign lymphoid hyperplasia of the orbit with rituximab. Ophthal Plast Reconstr Surg 26(1):11-3, Jan-Feb, 1/2010. PMID: 20090476.
44. Berkova Z, Tao RH, Samaniego F. Milatuzumab - a promising new immunotherapeutic agent. Expert Opin Investig Drugs 19(1):141-9, 2010. PMID: 19968579.

Invited Articles

1. Samaniego FS, Matias KP. Studies of the Viral Origins of Some Cancers Lead to New Prevention Treatment Stratigies, 2004.
2. Pati S, Lee Y, Samaniego F. Urinary proteins with pro-apoptotic and anti-tumor activity. Apoptosis 5(1):17-24, 2/2000. PMID: 11227487.


1. Fowler N, Pinto RM, Chea CY, Neelapu SS, Turturro F, Hagemeister FB, Romaguera JE, Fanale MA, Fayad LE, Forbes S, Khan J, Feng L, Samaniego F, Nastoupil L. A Phase I Study of Lenalidomide Plus a Next Generation Ant-CD20 Antibody, Obinutuzumab, in Relapsed Indolent Lymphoma. Blood 126(23) (#2742), 12/2015.
2. Fanale MA, Wang Z, Ma W, Oki Y, Hagemeister FB, Fayad LE, Fowler N, Romaguera JE, Shah N, Chuang HH, Lei F, Horowitz SB, Chihara D, Wesson E, Hutto TY, Ruben C, Samaniego F, Muzzafar T, Piekarz R, Davis RE. Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B-and T-Cell Lymphomas. Blood 126(23) (#2705), 12/2015.
3. Chihara D, Oki YY, Westin JR, Nastoupil L, Fayad LE, Samaniego F, Wesson E, Ruben C, Horwoitz SB, Feng L, Carg N, Ahmed S, Khouri IF, Hosing Cm, Romaguera JE, Nathan F, Fanale M. High Response Rate of Romidepsin in Combination with ICE (Ifosfamide, Carboplatin and Etoposide) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: Updates of Phase I Trial. Blood 126(23) (#3987), 12/2015.
4. Chihara D, Ahmed MA, Oki Y, Westin JR, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez A, Fowler N, Wang M, Fayad LE, Davis RE, Nastoupil L. Management Strategies and Outcomes for Very Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood 126(23) (#1502), 12/2015.
5. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. Blood 126(23) (#2738), 12/2015.
6. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Rfractory PTCL-NOS and ATL. Blood 126(23) (#3984), 12/2015.
7. Sehgal L, Tamer K, Wang X, Mathur R, Berkova Z, Romaguera JE, Rodriguez A, Neelapu SS, Samaniego F. Tumor Microenvironment Regulates Survival of Mantle Cell Lymphoma Cells through Various Signaling Pathways. Blood 126(23) (#4775), 12/2015.
8. Mathur R, Sehgal L, Berkova Z, Neelapu S, Samaniego F. Inhibition of demethylase, JMJD3 sensitizes diffuse large B-cell lymphoma (DLBCL) to chemotgherapy. AACR Annual Meeting (#108), 4/2015.
9. Sehgal L, Berkova Z, Khashab T, Wang X, Romaguera JE, Rodriguez AE, Neelapu S, Samaniego F. Tumor microenviornment influences survival of mantle cell lymphoma-initiating cells through FGF/FGFR1 signaling. AACR Annual Meeting (#445), 4/2015.
10. Noorani M, Phansalkar K, Hagemeister FB, Romaguera JE, Fayad L, Rodriguez A, Samaniego F, Fanale M, Wang M, MD1, Oki Y, Turturro F, Westin JR, Kwak LW. SUV on Pre-Treatment FDG PET Scan Is Not Predictive of Outcome in Follicular Lymphoma after R-CHOP Therapy. Blood 124(21) (#1629), 12/2014.
11. Thomas SK, Haygood TM, Qazilbash MH, Melendez AG, Galvis R, Delasalle KB, Feng L, Richards TA, Samaniego F, Wang L, Shah JJ, Orlowski RZ, Weber DM. A Phase II Trial Of Bortezomib-Rituximab Followed By Autologous Stem Cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary Therapy Of Waldenström's Macroglobulinemia (WM). Blood 122(21) (#4396), 12/2013.
12. Samaniego F, Romaguera JE, Fowler Nathan, Fanale MA, Shah JJ, McLaughlin P, Pro B, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu S, Kwak LW. A Single Center Phase II Trial Of 90yttrium-Ibritumomab-Tiuxetan Produces High Response Rates As First-Line Therapy For Early Stage B Cell Indolent Lymphoma, Including Bulky Disease. Blood 122(21) (#4396), 12/2013.
13. Berkova Z, Ao X, Braun FK, Wise JF, Sehgal L, Samaniego F. CD74 Interferes With The Expression Of Fas Receptor On The Cell Surface. Blood 122(21) (#4263), 12/2013.
14. Oki Y, Noorani M, Davis RE, Neelapu SS, Rodriguez A, Hagemeister FB, Fowler N, Wang M, Fanale MA, Samaniego F, Dabaja BS, Pinnix C, Kwak LW, Romaguera JE, Khouri I, Westin JR, and Fayad LE. Double Hit Lymphoma: M.D. Anderson Experience. Blood 122(21) (#1776), 12/2013.
15. Hagemeister FB, Rodriguez MA, Deitcher SR, Younes A, Fayad L, Goy A, Dang NH, Forman A, McLaughlin P, Pro B, Romaguera JE, Samaniego F, Silverman JA, Sarris AH, Cabanillas F. Long Term Results Of a Phase 2 Study Of Vincristine Sulfate Liposome Injection (Marqibo®) Substituted For Non-Liposomal Vincristine In CHOP With Or Without Rituximab For Patients With Untreated Aggressive Non-Hodgkin’s Lymphomas. Blood 122(21) (#3033), 12/2013.
16. Braun FK, Mathur R, Sehgal L, Berkova Z, and Samaniego F. Histone 3 Methyltransferase (EZH2) Inhibition Enhances TRAIL-Induced Apoptosis In Mantle Cell Lymphoma Cells By Accelerated cFLIP Degradation. Blood 122(21) (#4425), 11/2013.
17. Samaniego F, Mathur R, Berkova Z, Braun FK. Histone 3 methyltransferase (EZH2) inhibition results in accelerated caspase-8 processing and enhances TRAIL-induced apoptosis in mantle cell lymphoma cells. 12th International Conference on Malignant Lymphoma, 6/2013.
18. Samaniego F, Wise J, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, McLaughlin P, McDonnell TJ, Patel K, Neelapu SS, Kwak LW, Berkova Z. Regulation of Fas-mediated Apoptosis by Nucleolin in B-cell Lymphomas. 12th International Conference on Malignant Lymphoma, 6/2013.
19. Fowler NH, Neelapu SS, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Orlowski RZ, Wang M, Turturro F, Oki Y, Lacerte LC, Samaniego F. Lenalidomide and Rituximab for Untreated Indolent Lymphoma: Final Results of a Phase II Study. Blood 120(21) (#901), 11/2012.
20. Tao RH, Berkova Z, Wise JF, Zhu H, Ao X, Chen Z, Zhuang W, Braun FK, Mathur R, Samaniego F. Mechanism of Regulating Fas Signaling by Promyelocytic Leukemia Protein (PML) and Its Dominant-Negative Mutant PMLRARα. Blood 120(21) (#1327), 11/2012.
21. Westin JR, Chu F, Fayad LE, Kwak LW, Fowler NH, Romaguera JE, Hagemeister FB, Fanale M, Samaniego F, Allen R, Feng L, Baladandayuthapani V, Rotem-Yehudar R, Neelapu SS. Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Blood 120(21) (#793), 11/2012.
22. Fanale MA, Lai CM, Rimes SA, Ramirez MM, Hagemeister FB, Fowler NH, Younes A, Fayad LE, Rodriguez MA, Turturro F, Samaniego F, Romaguera JE, Levin VA, Horowitz SB, Woolery JE, Milbourne A. Positive Maternal-Fetal Outcomes with Treatment of Lymphoma During Pregnancy: UT MD Anderson Cancer Center Prospective Experience. Blood 120(21) (#3670), 11/2012.
23. Oki Y, Westin JR, Fowler N, Neelapu S, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale M, Younes A, Rodriguez MA, Orlowski RZ, Wang M, Ouzounian ST, Samaniego F, Fayad L. R-HCVAD Alternating with R-Methotrexate Cytarabine in Younger Patients (pts) with IH and High-Risk Age Adjusted-IPI DLBCL. Blood 120(21) (#38707), 11/2012.
24. Samaniego F, Wise JF, Tao RH, Zhu H, Ao X, Chen Z, Zhuang W,Braun FK, Mathur R, Romaguera JE, Fayad L, Wang M, Peter McLaughlin PM, McDonnell TJ, Patel K, Neelapu SS, Kwak LW, Zuzana Berkova Z. Regulation of Fas-mediated Apoptosis in B-Cell Lymphomas by Nucleolin. Blood 120(21) (#2406), 11/2012.
25. Oki Y, Chuang H, Chasen B, Pan T, Fanale MA, Dabaja BS, Fowler NH, Romaguera JE, Fayad JE, Hagemeister FB, Rodriguez MA, Neelapu SS, Samaniego F, Kwak LW, Younes A. The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. Blood 120(21) (#1529), 11/2012.
26. Fowler N, Zhang M, Wang Z, Muzzafar T, Harun N, Baladandayuthapani V, Sharma R, Delgado D, Wallace M, Heise C, Lacerte LC, Samaniego F, Davis ER, Neelapu SS. Activation of T and NK Cells Following Lenalidomide Therapy in Patients with Follicular Lymphoma. Blood 120(21) (#1714), 2012.
27. Samaniego F, Berkova Z, Wise JF, Kerros C, Hawke DH, Karp JE, Lin H, Molldrem JJ, Tao R. Effects of Aprepitant on Drug Metabolism in Lymphoma Patients Receiving Multi-Day Chemotherapy Regimen of Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, + Rituxan (R/CHOP): Randomized, Cross-Over Study. Blood 118(21) (#2451), 12/2011.
28. Felipe Samaniego, Zuzana Berkova, Jillian F Wise, Celine Kerros, PhD, David H Hawke, Judith E. Karp Hui-Kuan Lin, Jeffrey J. Molldrem and Rong-Hua Tao. PML and PMLRARα Interact with Fas to Regulate Fas-Mediated Apoptosis In Vivo. (ASH Meeting Abstract). Blood 118(21) (#2451), 11/2011.
29. Felipe Samaniego, Zuzana Berkova, Jillian F Wise, Celine Kerros, David H Hawke, Judith E. Karp, Hui-Kuan Li, Jeffrey J. Molldrem, and Rong-Hua Tao. Anti-CD74 Antibody hLL1 Is Associated with Lymphoma and Chronic Lymphocytic Leukemia Cell Effects In Vivo. (ASH Meeting Abstract). Blood 118(21) (#3510), 2011.
30. Andreef M, Kojima K, Padmanabhan S, Strair R, Kirschbaum M, Maslak P, Hillmen P, O'brien S, Samaniego F, Borthakur G, Konopleva M, Vassilev L, Nichols G. A multi-center, open-label, phase I study of single agent RG7112, A first in class p53-MDM2 antagonist, in patients with relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lympyhocytic lymphomas (CLL/SCLL). Blood 116(21):287, 2010.
31. Batty N, Hagemeister FB, Romaguera JE, Rodriguez MA, McLaughlin P, Samaniego F, Copeland A, Dabaja BS, Younes A. ABVD chemotherapy with interferon for advanced-stage classical Hodgkin's lymphoma: A 10-year follow-up study. 2010 ASCO Annual Meeting Abstract (#8057), 2010.
32. Fowler NH, McLaughlin P, Hagemeister FB, Kwak LW, Fanale MA, Neelapu SS, Fayad L, Orlowski RZ, Wang M, Samaniego F. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma. 2010 ASCO Annual Meeting Abstract (#8036), 2010.
33. Perini GF, Romaguera MA, Rodriguez B, Pra A, Younes NH, Fowler FB, Hagemeister F, Samaniego F, Kwak LW, Fayad L. Diffuse large B-cell lymphoma (DLBCL) with bone marrow (BM) involvement. Clinical presentation, central nervous system (CNS) relapses, and outcomes of 121 patients treated at M. D. Anderson Cancer Center. 2010 ASCO Annual Meeting Abstract (#8072), 2010.
34. Tao RH, Berkova Z, Wise J, Daniluk U, Bai L, Ao X, Samaniego F. Direct suppression of Fas-Mediated apoptosis by PMLRARa through forming an apoptotic inhibitory complex with c-FLIP in acute promyelocytic leukemia. Blood 116(21):1297, 2010.
35. Okoroji GJ, de Padua Silva L, Saliba RM, Korbling M, McLaughlin P, Hosing C, Anderlini P, Alousi A, de Lima M, Kebriaei P, Popat U, Qazilbash M, Fayad L, Samaniego F, Fowler N, Champlin R, Hagemeister F, Khouri I. Outcome in follicular lymphoma (FL) patients (pts) relapsing after autologous stem cell transplantation (ASCT): allografting vs. conventional therapy. Blood 116(21):1442, 2010.
36. Fanale MA, Chao-Ming L, McLaughlin P, romaguera J, Fayad L, Hagemeister F, Samaniego F, Rodriguez MA, Neelapu SS, Shah JJ, Kwak L, Dong W, Reed V, Dabaja BS, Popat U, younes A. Outcomes of nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL) patients treated with R-CHOP. Blood 116(21):1159, 2010.
37. Manoukian GE, Hagemeister FB, McLaughlin P, Fayad L, Samaniego F, Goy A, Romaguera JE, Pro B, Cabanillas F, Rodriguez MA. Rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) for patients with relapsed indolent B-cell lymphoma (RIL). 2010 ASCO Annual Meeting Abstract (#8078), 2010.

Manuals, Teaching Aids, Other Teaching Publications

1. Samaniego, F, Matias KP. Studies of the viral orgins of some cancers lead to new prevention, treatment strategies, 2004.
2. Samaniego F. The viral origins of lymphomas, 2002.

Last updated: 8/29/2016